Page last updated: 2024-08-23

raloxifene hydrochloride and medroxyprogesterone

raloxifene hydrochloride has been researched along with medroxyprogesterone in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	5 (55.56)	29.6817
2010's	2 (22.22)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dauvois, S; Dumont, M; Hatton, AC; Labrie, C; Labrie, F; Mérand, Y; Poirier, D; Poulin, R; Simard, J; Zhao, HF	1
Anderson, PW; Barrett-Connor, E; Collins, P; Cox, DA; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Wenger, NK	1
Ettinger, B	1
Jordan, VC	1
Bofilis, E; Iliodromitis, EK; Kremastinos, DT; Kyriakides, ZS; Sbarouni, E	1
Alexandrou, A; Christodoulakos, G; Creatsas, G; Lambrinoudaki, I; Liakakos, T; Panoulis, C; Papadias, C; Sarandakou, A	1
Carranza Lira, S; González Legorreta, SL; MacGregor Gooch, AL; Martínez Chéquer, JC; Olivares, A; Saldívar, N	1
Hayashi, T; Ina, K; Maeda, M; Nomura, H	1
Brito, LG; Candido Dos Reis, FJ; Ferriani, RA; Martins, WP; Moroni, RM; Nastri, CO; Vieira, CS	1

Reviews

2 review(s) available for raloxifene hydrochloride and medroxyprogesterone

Article	Year
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Add-back therapy with GnRH analogues for uterine fibroids. The Cochrane database of systematic reviews, 2015, Mar-20, Issue:3 Topics: Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estriol; Female; Gonadotropin-Releasing Hormone; Humans; Isoflavones; Leiomyoma; Medroxyprogesterone; Norpregnenes; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Hemorrhage; Uterine Neoplasms	2015

Article

Year

Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.

Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1

Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen

2001

Add-back therapy with GnRH analogues for uterine fibroids.

The Cochrane database of systematic reviews, 2015, Mar-20, Issue:3

Topics: Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estriol; Female; Gonadotropin-Releasing Hormone; Humans; Isoflavones; Leiomyoma; Medroxyprogesterone; Norpregnenes; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Hemorrhage; Uterine Neoplasms

2015

Trials

3 trial(s) available for raloxifene hydrochloride and medroxyprogesterone

Article	Year
Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. European journal of endocrinology, 2004, Volume: 151, Issue:2 Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Greece; Humans; Medroxyprogesterone; Middle Aged; Norpregnenes; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Vascular Endothelial Growth Factor A	2004
[Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women]. Ginecologia y obstetricia de Mexico, 2005, Volume: 73, Issue:10 Topics: Complement C3; Complement C4; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis. Nitric oxide : biology and chemistry, 2011, May-31, Volume: 24, Issue:4 Topics: Adiponectin; Aged; Blood Glucose; Bone Density; Cholesterol, HDL; Cholesterol, LDL; Estriol; Estrogen Replacement Therapy; Female; Humans; Japan; Medroxyprogesterone; Nitric Oxide; Osteoporosis; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Necrosis Factor-alpha	2011

Other Studies

4 other study(ies) available for raloxifene hydrochloride and medroxyprogesterone

Article	Year
Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. Annals of the New York Academy of Sciences, 1990, Volume: 595 Topics: Androgens; Androstenediol; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dihydrotestosterone; Estrogens; Gene Expression; Glucocorticoids; Glycoproteins; Humans; In Vitro Techniques; Insulin; Medroxyprogesterone; Medroxyprogesterone Acetate; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured	1990
Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas, 1998, Nov-30, Volume: 31, Issue:1 Topics: Coronary Disease; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Meta-Analysis as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Women's Health	1998
Meeting the evolving therapeutic needs of postmenopausal women. Journal of bone and mineral metabolism, 2000, Volume: 18, Issue:5 Topics: Aged; Drug Therapy, Combination; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. European journal of pharmacology, 2003, Apr-25, Volume: 467, Issue:1-3 Topics: Animals; Drug Therapy, Combination; Estrogen Antagonists; Estrogens; Female; Hypercholesterolemia; Medroxyprogesterone; Myocardial Infarction; Necrosis; Ovariectomy; Progesterone Congeners; Rabbits; Raloxifene Hydrochloride	2003